Professor | Fan Lin | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Fan Lin
Contact Information	linfan@njmu.edu.cn
Language ability	English, Chinese, Dutch
Province	Jiangsu

Upload Avatar (500 x 500)

Name

Fan Lin

Contact Information

linfan@njmu.edu.cn

Language ability

English, Chinese, Dutch

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	1996-2000 Bachelor: Zhejiang University, Biology 2006-2008 Master's: University of Amsterdam, Medical Biochemistry 2009-2013 PhD: Utrecht University-Netherlands Cancer Institute, Clinical Pharmacology Published over 20 papers in international cancer journals Authored an English monograph Received two national invention patents
Work Experience	2000-2003 - BGI - Genome Analyst 2013-2016 - National University of Singapore - Research Fellow 2016-present - Nanjing Medical University - Professor

University/Lab Affiliation and Title

Nanjing Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

1996-2000 Bachelor: Zhejiang University, Biology
2006-2008 Master's: University of Amsterdam, Medical Biochemistry
2009-2013 PhD: Utrecht University-Netherlands Cancer Institute, Clinical Pharmacology
Published over 20 papers in international cancer journals
Authored an English monograph
Received two national invention patents

Work Experience

2000-2003 - BGI - Genome Analyst
2013-2016 - National University of Singapore - Research Fellow
2016-present - Nanjing Medical University - Professor

Areas of Focus	Precision and combination therapy of tumor-targeted drugs CRISPR/Cas9 functional genomic screening for new targets in malignant tumor treatment Treatment of glioblastoma and drug delivery across the blood-brain barrier Tumor, aging, and senescence-associated secretory phenotype Tumor animal models
Publications	Radiomics features based on internal and marginal areas of the tumor for the preoperative prediction of microsatellite instability status in colorectal cancer, Ma Y, Lin C, Liu S, Wei Y, Ji C, Shi F, Lin F, Zhou Z, 2022 Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes, Wang Q, Li J, Zhu J, Mao J, Duan C, Liang X, Zhu L, Zhu M, Zhang Z, Lin F, Guo R, 2022 Activatable autophagy inhibition-primed chemodynamic therapy via targeted sandwich-like two-dimensional nanosheets, Wu H, Fu H, Wu F, Zhou T, Wang WH, Hu Z, Liang X, You C, Sun B, Lin F, 2022 A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells, Hu Z, Zhou T, Lin F, 2021 Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors, Chen C, Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, Chen L, Yan J, Hua Y, Lin F, 2020 A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors, Chen Z, Chen C, Zhou T, Duan C, Wang Q, Zhou X, Zhang X, Wu F, Hua Y, Lin F, 2020 PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models, Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O, 2017 Proteomic profiling predicts drug response to novel targeted anticancer therapeutics, Lin F, Li Z, Hua Y, Lim YP, 2016 Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery, Lin F, Tan H. J., Guan J. S., Lim Y. P., 2014 ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy, Lin F, de Gooijer MC, Moreno Roig E, Buil L, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, van Tellingen O, 2014 Abcc4 together with Abcb1 and Abcg2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs, Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O, 2013 Sildenafil is not a useful inhibitor of ABCB1 and ABCG2 in vivo, Lin F, Hogendijk H, Beijnen JH, van Tellingen O, 2013 Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2, Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O, 2013 Targeting on Core (Mutated) Pathways of High-grade Gliomas: Challenges of Intrinsic Resistance and Drug Efflux Transporters, Lin F, Beijnen JH, van Tellingen O, 2013 Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection, Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O, 2012 High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates, Lin F, Sherris D, Beijnen JH, van Tellingen O, 2011

Areas of Focus

Precision and combination therapy of tumor-targeted drugs
CRISPR/Cas9 functional genomic screening for new targets in malignant tumor treatment
Treatment of glioblastoma and drug delivery across the blood-brain barrier
Tumor, aging, and senescence-associated secretory phenotype
Tumor animal models

Publications

Radiomics features based on internal and marginal areas of the tumor for the preoperative prediction of microsatellite instability status in colorectal cancer, Ma Y, Lin C, Liu S, Wei Y, Ji C, Shi F, Lin F, Zhou Z, 2022
Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes, Wang Q, Li J, Zhu J, Mao J, Duan C, Liang X, Zhu L, Zhu M, Zhang Z, Lin F, Guo R, 2022
Activatable autophagy inhibition-primed chemodynamic therapy via targeted sandwich-like two-dimensional nanosheets, Wu H, Fu H, Wu F, Zhou T, Wang WH, Hu Z, Liang X, You C, Sun B, Lin F, 2022
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells, Hu Z, Zhou T, Lin F, 2021
Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors, Chen C, Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, Chen L, Yan J, Hua Y, Lin F, 2020
A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors, Chen Z, Chen C, Zhou T, Duan C, Wang Q, Zhou X, Zhang X, Wu F, Hua Y, Lin F, 2020
PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models, Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O, 2017
Proteomic profiling predicts drug response to novel targeted anticancer therapeutics, Lin F, Li Z, Hua Y, Lim YP, 2016
Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery, Lin F, Tan H. J., Guan J. S., Lim Y. P., 2014
ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy, Lin F, de Gooijer MC, Moreno Roig E, Buil L, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, van Tellingen O, 2014
Abcc4 together with Abcb1 and Abcg2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs, Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O, 2013
Sildenafil is not a useful inhibitor of ABCB1 and ABCG2 in vivo, Lin F, Hogendijk H, Beijnen JH, van Tellingen O, 2013
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2, Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O, 2013
Targeting on Core (Mutated) Pathways of High-grade Gliomas: Challenges of Intrinsic Resistance and Drug Efflux Transporters, Lin F, Beijnen JH, van Tellingen O, 2013
Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection, Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O, 2012
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates, Lin F, Sherris D, Beijnen JH, van Tellingen O, 2011

Tumor-Targeted Drugs Precision Therapy Combination Therapy Crispr/Cas9 Genomic Screening Glioblastoma Blood-Brain Barrier Aging Senescence Animal Models

Yang Zhao - Zhejiang University

Lulu Chen - Nanjing Medical University

Wenbing Xie - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us